QR 504a
Alternative Names: QR-504; QR-504a; QRX-504Latest Information Update: 07 Jul 2022
At a glance
- Originator ProQR Therapeutics
- Class Antisense RNA; Eye disorder therapies; Oligonucleotides
- Mechanism of Action RNA interference; RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Fuchs' endothelial dystrophy
Most Recent Events
- 11 May 2022 ProQR withdrew a phase Ib Fuchs Focus trial in Fuchs' endothelial dystrophy in United Kingdom (Intravitreous, Injection) (NCT05052554)
- 30 Apr 2022 Suspended - Phase-I for Fuchs' endothelial dystrophy in USA (Intravitreous)
- 05 Aug 2021 Phase-I clinical trials in Fuchs' endothelial dystrophy in USA (Intravitreous) (NCT05052554)